Identification of ZAG Protein as a Novel Serologic Biomarker Candidate for Liver Cancer

Fei Wang; Yu Geng; Wei Ming Zhang; Xin Geng

doi:10.4028/www.scientific.net/AMR.340.383

Paper Titles

Study of Supervised Segmentation Algorithm Based on Ant Colony for Putamen Region in Brain MRI
p.357

Nitric Oxide-Donating Derivatives of Chrysin Stimulate Angiogenesis and Upregulating VEGF Production
p.363

Study on Nitrogen, Phosphor and Chemical Oxygen Demand of Differnt Categories of Aquaculture Lakes by Means of Principal Component Analysis, Factor Analysis and Cluster Analysis
p.369

Research on Temperature Compensation for Long-Period Fiber Grating with Strain Property
p.378

Identification of ZAG Protein as a Novel Serologic Biomarker Candidate for Liver Cancer
p.383

Bioinformatics Analysis of Zinc-Alpha2-Glycoprotein，a Potential Serological Marker for Hepatocellualr Carcinoma
p.390

A Density Functional Theory Study on the McLafferty-Type Rearrangement in evenElectron Ions under Electrospray Ionization (ESI) Conditions
p.397

Synthetic Aperture Focusing Technique and Contrast Source Inversion Algorithm Applied in Elastic Wave Imaging
p.402

The Study of Apoptosis Induced by Allicin in HT-9/HL-60 and its Transfection Cell
p.409

HomeAdvanced Materials ResearchAdvanced Materials Research Vol. 340Identification of ZAG Protein as a Novel Serologic...

Identification of ZAG Protein as a Novel Serologic Biomarker Candidate for Liver Cancer

Abstract:

To identify Zinc-alpha-2-glycoprotein (ZAG) expression in HCC for serum biomarker, by analyzing the serum proteome of the patients suffering from primary hepatocellular carcinoma (HCC), liver cirrhosis and healthy donors. The serum proteome of the patients from HCC, liver cirrhosis and healthy donors were separated and identified by two-dimensional electrophoresis. The differentially expressed proteins were analyzed by peptide mass fingerprint based on MALDI-TOF-MS and SWISS-PROT or BLAST nr database searching. RT-PCR and Western blotting analysis were used to confirm expression of ZAG in HCC. Five differentially expressed proteins were identified. Albumin, Serotransferrin, CD5 antigen-like precursor ( IgM - associated peptide) were down-regulated in HCC, ZAG and Ig gamma-1 chain C region were up-regulated in HCC. ZAG, a lipid mobilizing factor, is a member of the major histocompatibility complex (MHC) class I family of protein. Five proteins which were found differentially expressed in HCC provided useful information for screening diagnostic tumor markers of human HCC. ZAG might be a novel candidate serum biomarker for HCC early diagnosis.

You might also be interested in these eBooks

View Preview

Info:

Periodical:

Advanced Materials Research (Volume 340)

Pages:

383-389

DOI:

https://doi.org/10.4028/www.scientific.net/AMR.340.383

Citation:

Cite this paper

Online since:

September 2011

Authors:

Fei Wang, Yu Geng, Wei Ming Zhang, Xin Geng

Keywords:

Candidate Biomarker, Hepatic Cancer, Proteomics, Zinc-Alpha-2-Glycoprotein

Export:

RIS, BibTeX

Price:

Permissions:

Request Permissions

References

[1] Cai Z, Chiu JF, He QY. Application of proteomics in the study of tumor metastasis. Genomics Proteomics Bioinformatics. 2(3): 152-66, Aug (2004).

DOI: 10.1016/s1672-0229(04)02021-2

Google Scholar

[2] Arrell DK, Neverova I, Van Eyk JE. Cardiovascular proteomics: evolution and proentia. Circ Res. 27; 88(8): 763-73. Apr (2001).

DOI: 10.1161/hh0801.090193

Google Scholar

[3] Li Y, Geng X, Zhang W. Application of proteomics to the study of hepatocellular carcinoma and some related diseases. Chinese J Clinical Oncology 2(6), 903-906, Oct (2005).

DOI: 10.1007/bf02789663

Google Scholar

[4] Peng XQ, Wang F, Geng X, Zhang WM. Current advances in tumor proteomics and candidate biomarkers for hepatic cancer. Exp Rev Proteomics. 6 (5), 551-561. (2009).

DOI: 10.1586/epr.09.72

Google Scholar

[5] Poon TC, Johnson PJ. Proteome analysis and its impact on the discovery of serological tumor markers. Clin Chim Acta. 313(1-2): 231-239. Nov (2001).

DOI: 10.1016/s0009-8981(01)00677-5

Google Scholar

[6] Steel LF, Shumpert D, Trotter M, et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics. 3(5): 601-609. May (2003).

DOI: 10.1002/pmic.200300399

Google Scholar

[7] Xu XQ, Leow CK, Lu X, et al. Molecular classification of liver cirrhosis in a rat model by proteomics and bioinformatics. Proteomics. 4(10): 3235-3245. Oct (2004).

DOI: 10.1002/pmic.200400839

Google Scholar

[8] Lim SO, Park SJ，Kim W, et al. Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun. 8; 291(4): 1031-1037. May (2002).

Google Scholar

[9] Geng X, Wang F, Li YG, et al. SELDI-TOF MS ProteinChip technology for screening of serum markers of HBV-induced hepatocellular carcinoma. J Exp Clin Cancer Res. 26 (4), 505-508, (2007).

DOI: 10.5353/th_b3639243

Google Scholar

[10] Matos JM, Witzmann FA, Cummings OW, et al. A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J Surg Res. 155(2): 237-43. (2009).

DOI: 10.1016/j.jss.2008.06.008

Google Scholar